Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Tobam

Tobam decreased its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 40.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 28,922 shares of the biotechnology company’s stock after selling 19,968 shares during the quarter. Tobam’s holdings in Sarepta Therapeutics were worth $3,517,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Janus Henderson Group PLC boosted its position in Sarepta Therapeutics by 14.2% in the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock valued at $544,408,000 after buying an additional 543,143 shares during the period. Wellington Management Group LLP raised its stake in shares of Sarepta Therapeutics by 32.3% in the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock valued at $340,527,000 after acquiring an additional 665,087 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Sarepta Therapeutics by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock valued at $211,910,000 after purchasing an additional 44,306 shares during the period. Jacobs Levy Equity Management Inc. grew its stake in Sarepta Therapeutics by 9.2% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 753,845 shares of the biotechnology company’s stock worth $94,148,000 after purchasing an additional 63,437 shares in the last quarter. Finally, Erste Asset Management GmbH purchased a new stake in Sarepta Therapeutics during the 3rd quarter worth about $79,425,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Piper Sandler decreased their price objective on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research note on Wednesday, November 27th. Jefferies Financial Group initiated coverage on shares of Sarepta Therapeutics in a report on Monday, October 21st. They set a “buy” rating and a $165.00 price target for the company. Cantor Fitzgerald upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $152.00 to $167.00 in a report on Thursday, November 7th. Evercore ISI dropped their target price on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. Finally, HC Wainwright reiterated a “sell” rating and issued a $75.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, January 30th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $178.71.

Sarepta Therapeutics Stock Performance

NASDAQ SRPT opened at $112.11 on Friday. The stock has a market capitalization of $10.71 billion, a price-to-earnings ratio of 89.69 and a beta of 0.75. The business’s 50 day moving average is $121.56 and its two-hundred day moving average is $126.35. Sarepta Therapeutics, Inc. has a 12-month low of $102.15 and a 12-month high of $173.25. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93.

Insider Buying and Selling

In related news, Director Kathryn Jean Boor sold 1,636 shares of the company’s stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the sale, the director now owns 5,880 shares in the company, valued at $738,234. This represents a 21.77 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the transaction, the director now directly owns 22,840 shares of the company’s stock, valued at approximately $2,851,345.60. This represents a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by corporate insiders.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.